A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
IL-17A Inhibitor Switching – Efficacy of Ixekizumab Following Secukinumab Failure. A Single-Center Experience
2019
Acta Dermato-Venereologica
Interleukin-17A inhibitors are a promising alternative to tumor necrosis factor-α inhibitors for the treatment of psoriasis. In-class switch has been hardly investigated for interleukin-17A inhibitors. We report the experience (2017-2018) of a tertiary medical center with interleukin-17A-inhibitor switch in patients with moderate-to-severe psoriasis. Patient-, disease- and outcome-related data were retrospectively collected from the electronic files of 25 patients switched to ixekizumab
doi:10.2340/00015555-3200
pmid:31017250
fatcat:skzpgtfsnfcm5ax35rswv3taiu